Stockreport

Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting

FIVE PRIME THERAPEUTICS  (FPRX) 
Last five prime therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.fiveprime.com/investor-relations
PDF SOUTH SAN FRANCISCO, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discoveri [Read more]